New Daiichi Structure Strengthens Oncology Focus
US-Based Global Unit Formed
Executive Summary
Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.
You may also be interested in...
AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
Pandemic Drives China Surge In Asia 100 Sales
Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.